Published: May 31, 2007

Introduction {#sec1}
============

Chronic lymphocytic leukemia (CLL) is one of the most common types of adult leukemias and is currently incurable. There were 8190 new cases of CLL in the United States in 2004 ([@bib28]). Familial occurrence of CLL has been noted in up to 10% of cases ([@bib52]); however, large pedigrees with many affected individuals are exceedingly rare. Most familial agglomerations consist of two or three affected first- or second-degree relatives ([@bib43]). Large case-control studies concluded that the risk ratio (RR), a measurement of the disease frequency in first-degree relatives of probands, was higher for CLL than for most other cancers ([@bib23]). While the average RR for all cancers in a US study was approximately 2.1, CLL showed a RR of 5.0, the fourth highest of all cancers ([@bib23], [@bib39]). For CLL a RR of 7.5 was recently calculated in Sweden ([@bib25]). In a study of the entire Icelandic population, lymphoid leukemia had the second highest RR of all malignancies studied ([@bib1]).

This evidence of high heritability has prompted investigators to conduct genome-wide searches for linkage in samples from CLL families. The findings, in particular from one US and one European-led consortium ([@bib24], [@bib43]), have been limited due to weak evidence for linkage at several loci, most of which were different between the two studies. Loci in chromosome bands 11p11 and 13q21, respectively, were backed by statistically significant evidence, but no gene has been implicated to date.

Studies uncovering epigenetic aberrations in CLL have accelerated the search for CLL-related genes. A genome-wide DNA methylation analysis of CLL samples identified almost 200 novel epigenetically silenced genes in CLL. The study concluded that on average 4.8% of all CpG islands in a CLL genome could be targeted for aberrant DNA methylation and associated gene silencing ([@bib42]). The role of aberrant methylation in CLL was highlighted by the finding of preferential promoter methylation-directed gene silencing of *ZAP-70* and *TWIST2* in subgroups of CLL defined by IgV~H~ mutational status ([@bib14], [@bib37]). The emerging concept from these findings is that DNA methylation contributes significantly to global expression changes that have been described for CLL ([@bib40]).

Here, we combined epigenetic and genetic data to identify a novel putative tumor suppressor in CLL. We present evidence that epigenetic silencing and/or germline mutations in *death-associated protein kinase 1* (*DAPK1*), a positive mediator of apoptosis, contribute to familial CLL and that this gene is silenced in virtually all cases of sporadic CLL.

Results {#sec2}
=======

Frequent Epigenetic Inactivation of *DAPK1* in CLL {#sec2.1}
--------------------------------------------------

*DAPK1* was initially isolated as a positive mediator of apoptosis induced by interferon-γ (INF-γ) ([@bib16]). Previous studies, using methylation-specific PCR (MSP), demonstrated low frequencies of aberrant DNA methylation of the *DAPK1* promoter in CLL ([@bib10], [@bib29]). We expanded the analysis of DNA methylation events in the *DAPK1* CpG island and performed quantitative high-throughput analysis of DNA methylation in four amplicons using the MassARRAY system ([Figure 1](#fig1){ref-type="fig"}A). The number of CpGs studied in amplicons A1--A4 was 17, 22, 20, and 29, respectively. The average DNA methylation frequency in four samples of normal peripheral blood mononuclear cells (PBMCs) isolated from healthy volunteers and seven samples of normal CD19+ B cells was 6.3% and 7.6% (range 5.1%--8.9%), respectively. In contrast, we saw an average of 64% (range 55.9%--83.9%) DNA methylation in seven CD19+ selected CLL samples ([Figure 1](#fig1){ref-type="fig"}B). Next, we evaluated the PBMCs from 62 sporadic CLL patient samples. These CLL samples showed varying levels of *DAPK1* promoter methylation, ranging from 7.2% to 66.1%. Only 2 out of 62 CLL samples (marked as ^∗^ in [Figure 1](#fig1){ref-type="fig"}A) showed methylation levels in the normal range (\<11%), whereas all other samples showed levels \>11%. The distribution of DNA methylation levels in CLL samples is significantly different from the one seen in normal cells (p \< 0.0001). Raji cells were methylated (83.9%), whereas Jurkat cells were unmethylated in regions A1--A3 but methylated in A4. In addition, we tested the DNA methylation status in several leukemia/lymphoma cell lines---Ramos (Burkitt lymphoma), BJAB (atypical Burkitt lymphoma \[EBV−\]), MEC-1 (CLL), MEC-2 (CLL), Wac3CD5 (CLL), Daudi (Burkitt lymphoma), 697 (ALL), RS11846 (Non-Hodgkin lymphoma), and RS 4;11 (ALL) ---using COBRA for the two most densely methylated regions in the *DAPK1* promoter. With the exception of Wac3CD5, all cell lines demonstrated aberrant DNA methylation as compared to CD19+ selected B cells ([Figures S1](#app2){ref-type="sec"}A and S1B). Chromatin immunoprecipitation (ChIP) assay, using antiacetylated histone H3 and H4 antibodies, showed that in Raji cells (methylated), the *DAPK1* promoter was not associated with either ac-H3 or ac-H4 histones, while in WaC3CD5 and Jurkat cell lines (unmethylated) acetylated histones were found within this region ([Figures S1](#app2){ref-type="sec"}C--S1F).

To study the relevance of promoter methylation for *DAPK1* expression, we developed luciferase reporter constructs to test *DAPK1* promoter activity in Jurkat cells. *DAPK1* promoter construct no. 2 (c.1-1545--c.1-1151 bp), covering bisulfite region A1 showed a 30-fold increase in the reporter activity relative to the vector control ([Figure 2](#fig2){ref-type="fig"}A). Semiquantitative RT-PCR analysis of CD19+ CLL samples used in [Figure 1](#fig1){ref-type="fig"}A showed reduced *DAPK1* expression in all seven samples ([Figure 2](#fig2){ref-type="fig"}B). Furthermore, *DAPK1* expression in 50 unselected CLL cells also showed statistically significant (p \< 0.01) reduction as compared to normal CD19+ B cells ([Figure 2](#fig2){ref-type="fig"}C). The functional relevance of *DAPK1* promoter methylation was tested in a reporter assay in which the promoter sequence of construct no. 2 ([Figure 2](#fig2){ref-type="fig"}A) was ligated either following *Sss*I treatment or untreated. Luciferase expression was 5-fold reduced in the methylated construct, further augmenting the finding that *DAPK1* promoter methylation results in gene silencing ([Figure 2](#fig2){ref-type="fig"}D).

Next, we treated Raji cells with 0.5 μM Decitabine for 3, 6, 9, and 12 days. RT-PCR for *DAPK1* indicated that Decitabine treatment resulted in gradual upregulation of *DAPK1* expression, while untreated Raji cells did not show any detectable expression ([Figure 2](#fig2){ref-type="fig"}E). Bisulfite sequencing of the BS1 region showed that 116 of the tested 210 CpG dinucleotides (55%) were methylated in untreated Raji cells. Treatment with Decitabine resulted in significantly (p \< 0.001) reduced DNA methylation with 29% (70/240) on day 6 and 25% (68/270) on day 12 ([Figure 2](#fig2){ref-type="fig"}F).

*DAPK1* Regulates Apoptosis in a Lymphoid Cell Line {#sec2.2}
---------------------------------------------------

We stably transfected Jurkat cells with *DAPK1* siRNA that resulted in its downregulation ([Figure 3](#fig3){ref-type="fig"}A). Cells transfected with vector alone or *DAPK1* siRNA were treated with activating anti-Fas antibody, and apoptosis was examined using annexin-V-FITC/Propidium Iodide (annexin/PI) flow cytometry. Jurkat cells with inhibited *DAPK1* expression showed a statistically significant increase in resistance to apoptosis compared to cells transfected with vector alone (p \< 0.001; [Figure 3](#fig3){ref-type="fig"}B). These data demonstrated that DAPK1 is involved in Fas-induced extrinsic apoptosis in lymphoid cells. Next, we incubated 5 × 10^7^ cells from nine CLL patients with or without Fas-activating antibody (50 or 100 ng/ml) for 24 hr and examined apoptosis by annexin/PI flow cytometry ([Table S1](#app2){ref-type="sec"}). No significant effect on the percentage of nonapoptotic cells relative to the untreated control was seen (data not shown). Immunoblot analysis to assess potential changes in p53 expression following treatment showed no detectable differences ([Figure 3](#fig3){ref-type="fig"}C). In conclusion, these experiments are in line with our current knowledge that DAPK1 is a mediator of Fas-induced apoptotic signaling and loss of DAPK1 in CLL cells renders resistance to apoptosis ([@bib13], [@bib38]).

A CLL Family with Linkage to Chromosome 9 {#sec2.3}
-----------------------------------------

Lynch and colleagues previously documented an extended family in which a father and four sons were diagnosed with CLL ([@bib33]). We have since identified additional family members, both affected and unaffected ([Figure 4](#fig4){ref-type="fig"}A). Genome-wide linkage analysis with a panel of 400 microsatellite markers was performed using samples from individuals III-2, III-3, III-4, IV-3, IV-4, and IV-5. This identified a region on chromosome 9 between markers *D9S175*--*D9S1776* with the highest nonparametric linkage (NPL) score of 0.96. The next highest scores were less than 0.42. High-resolution genotyping identified a common haplotype of 707 kb in all affected family members for whom samples were available. The segment of the presumed CLL haplotype includes three known genes (*DAPK1*, *CTSL*, and *CCRK*) and 11 predicted genes. Based on the epigenetic data indicating frequent loss of *DAPK1* expression, we hypothesized that *DAPK1* might be the predisposing gene mutated in this family. All exons and splice sites of *DAPK1* were sequenced from DNA of the skin fibroblasts of four affected (III-2, III-3, III-4, and IV-5) as well as two unaffected family members (IV-3 and IV-4) and compared to the genomic sequence (NM_004938). Although five DNA variants were detected (one in exon 3, two in exon 16, and two in exon 26), none was unique for the CLL haplotype. These variants were useful in RT-PCR analysis of *DAPK1* and showed that gene expression was highly reduced in the CLL allele of patients III-4 and III-3, whereas both wild-type (WT) alleles were equally expressed in unaffected individuals IV-3 and IV-4 ([Figure 4](#fig4){ref-type="fig"}B).

Allelic Expression Imbalance in *DAPK1* in Affected Family Members {#sec2.4}
------------------------------------------------------------------

As a next step we developed monochromosomal mouse-human hybrid clones containing either the WT (one clone) or the CLL (two clones) chromosome 9 from patient III-4. Semiquantitative RT-PCR ([Figure 4](#fig4){ref-type="fig"}C) and immunoblotting ([Figure 4](#fig4){ref-type="fig"}D) showed reduced *DAPK1* expression from the two clones containing the CLL chromosome (25% or less) when compared to the clones containing the WT chromosome (100%). Reduced *DAPK1* expression from the CLL allele was further confirmed in diploid cells. We cloned RT-PCR products containing exon 16 comprising the informative single nucleotide polymorphism (SNP) c.1510A \> G from an unaffected (IV-3) and an affected (III-4) family member. Individual clones were genotyped by PCR using allele-specific primers. In individual IV-3, the ratio of A:G clones was close to the expected ratio of 1:1 ([Figure 4](#fig4){ref-type="fig"}E), while in individual III-4, the number of A-clones (WT allele) was approximately four times that of the G clones (CLL allele; [Figure 4](#fig4){ref-type="fig"}F), and this difference was statistically significant (p \< 0.01).

Detection of a Rare Germline Mutation by *DAPK1* Genomic Sequencing {#sec2.5}
-------------------------------------------------------------------

In search of a germline mutation in *DAPK1* regulatory sequences, we extended our genomic sequencing efforts. BAC clones derived from both the affected and the unaffected alleles of family member III-3 were generated, and two overlapping BAC clones for the CLL (CR956620 and CR956432) and the WT allele (CT009543 and CR974482) were chosen for shotgun sequencing. Approximately 400 kbp were sequenced for each allele, extending from 45 kb upstream to 100 kb downstream of *DAPK1*, covering the entire gene. No major rearrangements were detected in the sequence. In total, 281 single nucleotide differences were observed between the two alleles, out of which 162 were reported SNPs and 87 were located within repeat elements. We further eliminated 28 of the remaining 32 SNPs as candidate mutations, since they occurred in additional controls tested. One SNP seen in the CLL allele, c.1-6531A \> G, was not found among 383 control samples from the US (n = 281) and from Northern Europe (n = 102). Screening of 263 CLL cases from the US (n = 129) and from Northern Europe (n = 134) identified one additional CLL sample from Scandinavia with SNP c.1-6531A \> G. This Scandinavian sample (no. 102) showed the presence of this SNP in purified CLL cells and in T cells.

We further investigated samples from 75 CLL patients with one affected relative in order to determine if *DAPK1* is a target for genetic mutations. We amplified and sequenced all exonic sequences (including splice sites) and the c.1-6531 suppressor region. As control samples we included DNAs from Wac3CD5 and two healthy donors. We identified numerous SNPs in exons 1 (noncoding), 3, 4, 16, 18, 19, and 26; some of them had already been reported as common polymorphisms ([Table S2](#app2){ref-type="sec"}). We were unable to identify a missense mutation, a splice-site mutation, or an additional case with c.1-6531A \> G.

HOXB7 Represses *DAPK1* Transcription {#sec2.6}
-------------------------------------

To study the effect of c.1-6531A \> G on *DAPK1* transcription, corresponding CLL and WT luciferase reporter constructs were designed ([Figure 5](#fig5){ref-type="fig"}A). A 357 bp fragment including either c.1-6531A (DAP-A) or c.1-6531G (DAP-G) was ligated upstream into luciferase construct no. 1 containing the *DAPK1* promoter. Transcription from the DAP-A and DAP-G construct was suppressed by 39% and 70%, respectively, compared to control construct no. 1 ([Figure 5](#fig5){ref-type="fig"}B). This suggested that both sequences contain a suppressor element; however, the CLL-derived sequence, (DAP-G), displayed stronger effects.

To identify the potential suppressor molecule that binds at c.1-6531, an electrophoretic mobility shift assay (EMSA) was performed using oligonucleotides with either the WT oligo (A) or the CLL oligo (G). Using nuclear extracts from Jurkat cells, multiple bands were observed with both oligos (I--V; [Figure 5](#fig5){ref-type="fig"}C). Competition assays with unlabeled oligo confirmed specificity ([Figure 5](#fig5){ref-type="fig"}D). The specificity of binding was further illustrated by mutating one base on either side of the A or G within the respective oligos. [Figure 5](#fig5){ref-type="fig"}E shows that while the mutation in the WT oligo resulted in elimination of band V, the mutation in the CLL oligo resulted in elimination of bands IV and V. This result showed that protein binding at band IV is affected by the c.1-6531A \> G mutation. Although EMSA is not a quantitative assay, we observed in multiple independent experiments that the intensity of band IV with the CLL oligo was stronger than with the WT oligo, hinting at a differential binding strength ([Figures 5](#fig5){ref-type="fig"}C--5E). Transcription factor binding-site prediction suggested that HOX family proteins might have differential affinity to A or G at the c.1-6531 SNP. In supershift assays using two HOX family proteins (HOXB7 and MSX2), only the HOXB7 antibody induced a clear shift, suggesting that HOXB7, or another closely related HOX protein, interacts with this site ([Figure 5](#fig5){ref-type="fig"}F).

Next, we tested *DAPK1* as well as *HOXB7* expression in B cells, T cells, and granulocytes of three healthy donors and selected B cells from CLL patients. *DAPK1* expression was highest in normal B cells, and about one-fifth or one-third of the expression is seen in T cells and in granulocytes, respectively ([Figure S2](#app2){ref-type="sec"}). As shown above, expression of *DAPK1* was further reduced (or not detectable) in selected CLL cells. *HOXB7* was expressed equally in B and T cells, however much reduced in granulocytes. Interestingly, HOXB7 was variably expressed in selected CD19+ CLL cells with several samples showing increased expression ([Figure S2](#app2){ref-type="sec"}).

To explore whether HOXB7 affects *DAPK1* expression, we transfected skin fibroblasts from an affected (III-4) and an unaffected family member (IV-4) with *HOXB7* siRNA. Quantitative RT-PCR showed successful *HOXB7* downregulation in both samples on day 1 following transfection, while scrambled siRNA did not show this downregulation ([Figures 6](#fig6){ref-type="fig"}A and 6B). *DAPK1* upregulation in HOXB7 siRNA-transfected fibroblasts was observed in both III-4 and IV-4, showing that HOXB7 is a repressor of *DAPK1* expression ([Figures 6](#fig6){ref-type="fig"}C and 6D). In addition, allele-specific expression analysis was studied in skin fibroblast cells before and after siRNA HOXB7 transfection in family members III-4 and IV-4. RT-PCR products (days 0 and 2) comprising informative SNP c.1510A \> G were cloned, and individual clones were genotyped. In affected family member III-4, the increase in *DAPK1* expression from the CLL allele was significantly higher than in the WT allele (p \< 0.01), while the relative ratio between the two *DAPK1* alleles in unaffected family member IV-4 remained unchanged (p = 0.4) ([Figures 6](#fig6){ref-type="fig"}E and F6). These results show that *DAPK1* expression is downregulated by HOXB7 and suggest that c.1-6531A \> G increases the affinity of HOXB7 binding, resulting in stronger repression of *DAPK1* from the CLL allele.

*DAPK1* Promoter Methylation in CLL Cells of Affected Family Members {#sec2.7}
--------------------------------------------------------------------

Our results indicated that expression of the CLL allele was reduced to 25% compared to the WT allele in affected family members. Thus, total *DAPK1* expression was reduced to approximately 62.5% of that of normal levels. We hypothesized that additional *DAPK1* repression occurred due to promoter methylation. Indeed, *DAPK1* expression in PBMCs of five affected family members was remarkably downregulated when compared to three normal CD19+ cell controls ([Figure 7](#fig7){ref-type="fig"}A). Selected CD19+ B cells from blood of unaffected family members were not available as a control. Bisulfite sequencing of PBMC DNA from affected (III-1 and III-4) and unaffected family members (IV-1) for the BS1 and BS2 regions showed that both regions were highly methylated in the two affected family members ([Figure 7](#fig7){ref-type="fig"}B). Altogether, these data suggest that *DAPK1* expression in the affected family members is significantly reduced by a combination of epigenetic and genetic aberrations.

Discussion {#sec3}
==========

We identified downregulaion of *DAPK1* expression as a mechanism predisposing to CLL in a large family with seven individuals. A single nucleotide change enhances the binding affinity of transcription factor HOXB7 and results in downregulation of *DAPK1* transcription. Importantly, *DAPK1* is not only a target in familial CLL but is also inactivated in the majority of sporadic cases of CLL by epigenetic mechanisms. Interestingly, it has long been known that some high-penetrance genes (e.g., *MLH1*, *BRCA1*, *p16*) identified in familial cancers are also frequently silenced by epigenetic mechanisms in sporadic cancers ([@bib21]).

DAPK1 is an actin-filament-associated, calcium calmodulin-dependent, serine/threonine kinase that promotes apoptosis in response to various stimuli, including Fas, INF-γ, and TNF-α ([@bib2]). Increased *DAPK1* expression leads to death-associated cellular alterations and cell morphology changes ([@bib12]). The *DAPK1* promoter contains TGF-β response elements as well as p53-binding sites ([@bib34]). *DAPK1* overexpression results in upregulation of p53, suggesting a signaling feedback loop in which DAPK1 and p53 regulate each other\'s expression. DAPK1 suppresses cMYC- and E2F-induced cell transformation by activating p19^ARF^/p53-dependent apoptosis and also blocks tumor metastasis in vivo ([@bib26], [@bib38]). DAPK1 inhibits extracellular signal-regulated kinase (*ERK*) activity, counteracts its survival signal ([@bib8]), and promotes cytochrome c release from the mitochondria in response to TGF-β-induced apoptosis ([@bib27]).

The observed frequent silencing of *DAPK1* by promoter methylation in CLL could be one of the events required by the leukemic cells to escape cell death mediated by either the intrinsic or extrinsic pathways of apoptosis. Downregulation of DAPK1 by transfecting siRNA in Jurkat cells, an acute T cell leukemia cell line, resulted in reduced susceptibility to Fas-induced apoptosis. This suggests involvement of DAPK1 in the extrinsic apoptosis pathway in lymphocytes. Thus, it is reasonable to speculate that *DAPK1* silencing may be an additional mechanism contributing to malignant progression by conferring resistance to apoptosis.

Past efforts have identified numerous affected genes in CLL, most in regions of somatic genetic alterations, mainly deletions, which are frequently observed in sporadic CLLs ([@bib46]). For example, deletion of 13q14 is commonly seen in up to 50% of sporadic CLL ([@bib18]). Several candidate tumor-suppressor genes from this region have been proposed, including miR15 and miR16, two microRNAs targeting the oncogene BCL2 ([@bib4], [@bib11], [@bib35]).

Mapping efforts in CLL families have been relatively unsuccessful in identifying genes predisposing to CLL. Several candidate genes and predisposing polymorphisms have been proposed, including *ARLTS1*, a gene that resides on chromosome 13q14 ([@bib6]) and *P2RX7,* located on chromosome 12q24 ([@bib49]). However, this predisposition was not supported in follow-up studies ([@bib15], [@bib44], [@bib48]).

How can these previous linkage results be reconciled with our findings regarding the role of *DAPK1*? Heritable germline mutations of *DAPK1* itself may not underlie the disease in many of the larger CLL families that contributed to the previous linkage studies. The existence of multiple linkage peaks, none or few of which are statistically significant, suggests considerable locus heterogeneity or the existence of multiple mutated genes as recently proposed in an association study using nonsynonymous SNPs in candidate genes ([@bib7], [@bib41]). Since our results implicate downregulation of *DAPK1* not only as the primary susceptibility factor in a large family, but also as a major event in sporadic CLL, it is quite possible that *trans*-acting factors, such as RNA genes ([@bib5], [@bib20]), play roles in the deregulation of *DAPK1*, and other genes, in CLL.

The occurrence of reduced *DAPK1* expression in combination with frequent promoter methylation in tumor cells of familial CLL is intriguing. It is possible that reduced expression itself becomes a trigger for *DAPK1* promoter methylation, which is initiated by transcriptional silencing (or reduced expression), followed by chromatin condensation and histone tail modifications, and finally by DNA methylation. This sequence of gene silencing events has been shown for target genes in the estrogen receptor signaling pathway in breast cancer cells ([@bib30]) and for glutathione S-transferase in prostate cancer cells ([@bib47]). To explain the frequent occurrence of promoter methylation in sporadic CLL, one may postulate *DAPK1* silencing due to modulation of upstream signals. One of these signals, HOXB7, was identified in this work. HOXB7 is a homeobox-containing transcription factor mediating a variety of developmental processes, including hematopoietic differentiation and lymphoid development ([@bib32], [@bib45]). A scenario that may explain frequent targeting of the *DAPK1* promoter by aberrant DNA methylation is the aberrant recruitment of DNA methyltransferase activity to the *DAPK1* promoter by oncogenic proteins ([@bib3], [@bib17]).

In conclusion, we have identified *DAPK1* as a novel putative tumor suppressor gene in CLL. The combination of linkage analysis and epigenetic studies demonstrated that downregulation of *DAPK1* is common in CLL cells. The frequent silencing in sporadic CLL suggests that aberrant silencing of *DAPK1* is an early and required event in leukemogenesis. Screening of familial CLL cases for *DAPK1* promoter methylation could help in early diagnosis of CLL, which is a late onset disease. In addition, as DNA methylation events are reversible, our finding provides hope for the development of novel treatment regimens in CLL involving epigenetic therapies for gene reactivation.

Experimental Procedures {#sec4}
=======================

Patient Selection, Sample Collection, and Cell Lines {#sec4.1}
----------------------------------------------------

Blood and fibroblast cell lines were obtained from patients with B cell CLL through the CLL Research Consortium (CRC), from the Ohio State University (OSU), Creighton University (CU), and Uppsala University Hospital tissue banks. CLL patients and unaffected individuals from OSU, CU, and CRC provided written informed consent using Institutional Review Board-approved protocols. Written consent for Uppsala samples was provided according to the declaration of Helsinki. Seven CD19-selected sporadic CLL samples were obtained by positive selection using magnetic beads conjugated to anti-CD19 (MACS, Miltenyi Biotec, Auburn, CA). The resulting cells are at least 95% CD19 positive. All patients had immunophenotypically defined CLL as outlined by the modified NCI criteria ([@bib9]) and for Uppsala samples, according to the WHO classification. Cell lines WaC3CD5, Jurkat, Raji, lymphoblastoid cell lines generated from III-4, and skin fibroblasts from family 4532 were maintained in culture.

Quantitative DNA Methylation {#sec4.2}
----------------------------

Quantitative high-throughput DNA methylation analysis was done by MassARRAY system as described elsewhere ([@bib19]). Four bisulfite reactions (A1--A4) were designed, which covered 17, 20, 22, and 29 CpGs, respectively, and extend from c.1-1573 to c.1-239 bp. The primer sequences are available upon request. For follow-up methylation studies on selected samples, bisulfite sequencing was performed as described earlier ([@bib42]). Two bisulfite reactions covering regions c.1-1509--c.1-1262 (BS1) and c.1-1281--c.1-903 (BS2) were amplified.

Semiquantitative Reverse Transcriptase PCR (RT-PCR) {#sec4.3}
---------------------------------------------------

RT-PCR was performed and analyzed as described previously ([@bib37]) using SUPERSCRIPT First-Strand Synthesis kit (Invitrogen). SYBRgreen PCR was done in triplicates with IQ SYBR Green Supermix (Bio-Rad, Hercules, CA).

Development of Monochromosomal Mouse-Human Hybrid Clones {#sec4.4}
--------------------------------------------------------

Lymphoblastoid cells from samples III-4 was used to generate monoallelic clones as described previously ([@bib36]). Genotyping confirmed one clone with WT and two clones with CLL chromosome 9.

Expression Vectors and Luciferase Reporter Assay {#sec4.5}
------------------------------------------------

A modified pGL3 basic vector ([@bib50]) was used to ligate the PCR-amplified *DAPK1* promoter constructs. The SV40 promoter reporter construct served as positive control. Monochromosomal mouse-human hybrid cells were used to amplify SNP c.1-6531A \> G in a 357 bp fragment with either the A or the G allele. The PCR products were ligated into the pGL3-promoter vector at the *Xho*I site, and the SV40 promoter was replaced by *DAPK1* promoter region (c.1-2215--c.1-1151 bp) at the *Bgl*II and *Hin*dIII sites to create DAP-G or DAP-A constructs. Constructs were confirmed by sequencing. For transfection into Jurkat cells, a density of 1.5 × 10^5^ cells/well was used in a 24-well plate with no serum for 2 hr. After 2 hr 1 μg plasmid pGL3 vector and 20 ng of pRL-TK internal control vector (Promega) were cotransfected into cells using polyethylenimine (Polysciences, Warrington, PA). After 4 hr, RPMI medium with 10% FCS was added to each well to make up the volume to 1 ml. The cells were further incubated for 48 hr, and the luciferase assay was performed according to manufacturer\'s instructions (Promega). Luciferase activity was normalized using pRL-TK activity. Each experiment was performed in triplicate. The in vitro methylation assay was performed as recently described ([@bib51]).

siRNA Transfection {#sec4.6}
------------------

For stable transfection of *DAPK1* siRNA into Jurkat cells, the pRS vector with different *DAPK1* siRNA inserts (siRNA A and C) from OriGene, (Rockville, MD) were used. Ten micrograms of pRS-DAPK1 siRNA A, siRNA C, or pRS vector alone were transfected into the amphotropic Pheonix packaging cell line (60% confluent) using Superfect (Qiagen). Virus-containing medium was collected from the Pheonix cells after 48 hr, and cell debris was removed by centrifugation. One milliliter of fresh medium plus 1 ml of infectious medium, containing either pRS-DAPK siRNA A, siRNA C, or pRS vector alone were added to 2.5 × 10^5^ Jurkat cells/well, and the 6-well plate was centrifuged at 2300 rpm for 90 min at room temperature in a Beckman centrifuge GPH, Rotor 3.7. Following the centrifugation step, 2 ml of fresh medium was added, and, 48 hr after incubation in 5% CO~2~, cells were selected for puromycin resistance using medium supplemented with 2 μg/ml Puromycin (Sigma, St Louis, MO). For transient transfection of HOXB7 siRNA (Ambion, Austin, TX) into fibroblast cells, 2 × 10^5^ cells were plated, and 24 hr later cells were transfected using polyethylenimine (Polysciences, Warrington, PA), as described before.

Apoptosis and Flow Cytometric Studies {#sec4.7}
-------------------------------------

Jurkat cells stably transfected with pRS vector control or pRS-DAPK siRNA C were treated with 100 ng/ml anti-Fas (human activating, clone CH11) antibody (Upstate Biotechnology, Lake Placid, NY) for 16 hr and resuspended in binding buffer containing annexin V-fluorescein isothiocyanate (FITC) and propidium iodide according to the supplier\'s instuctions (BD Biosciences, San Diego, CA), and assessed by flow cytometry using a Beckman-Coulter model EPICS XL cytometer (Beckman-Coulter, Miami, FL). Each sample was run in triplicate.

Immunoblot Analysis {#sec4.8}
-------------------

Immunoblotting was performed by transferring proteins to a nitrocellulose membrane (Hybond-ECL, Amersham Biosciences, Germany). Following the DAPK1 (Sigma-Aldrich, St. Louis, MO) and α-tubulin antibody (Oncogene, Boston, MA) staining, the proteins were detected with chemiluminescent substrate (SuperSignal, Pierce, Rockford, IL).

SSCP Analysis and Genotyping of Alleles by Colony PCR {#sec4.9}
-----------------------------------------------------

PCR-amplified fragments were analyzed by single-strand conformation polymorphism (SSCP) as previously described ([@bib31]). Variant bands were reamplified and used for direct sequencing on ABI Prism 3730 DNA analyzer (Applied Biosystems). For genotyping of the alleles for c.1-1510A \> G SNP, cDNA was amplified and cloned. Colony PCR was performed in each samples by using primers specific to either "A" or the "G" SNP.

Electrophoretic Mobility Shift Assay (EMSA) {#sec4.10}
-------------------------------------------

The oligonucleotides used for EMSA were WT oligo 5′-cttgccttggtcgtgattacctacagatgcctgaat-3′, WT oligo mutant 5′-cttgccttggtcgtaactacctacagatgcctgaat-3′, CLL oligo 5′-cttgccttggtcgtggttacctacagatgcctgaat-3′, and CLL oligo mutant 5′-cttgccttggtcgtagctacctacagatgcctgaat-3′. The double-stranded oligonucleotides were end-labeled with \[γ-^32^P\]ATP using T4 polynucleotide kinase enzyme (NEB). The free probe was removed by purification in G50 Sephadex spin columns. The binding reaction was conducted at room temperature for 20 min with 5 μg of nuclear extract, 40,000 dpm (0.08--0.4 ng) of radiolabeled oligonucleotide probe, in 1x Ficoll buffer (10 mM Tris (pH 7.5), 1 mM DTT, 1 mM EDTA, and 4% Ficoll), 250 ng of poly(deoxyinosinic-deoxycytidylic acid) in 75 mM KCl, and double-distilled H2O to make the volume to 15 μl. For supershift assay, 1 μg each of HOXB7, MSX2 (Cemines, Golden, CO), and USF2 (Santa Cruz Biotechnologies, Santa Cruz, CA) was added, and the mixture was incubated at room temperature for an additional 30 min. DNA-protein complexes were fractionated by electrophoresis in 6% nondenaturating polyacrylamide gel, and radioactivity in the gels was visualized by autoradiography analyzed using the STORM860 image analyzer (Amersham Biosciences, NJ). Nuclear extracts from Jurkat cells were made as described previously ([@bib22]).

Statistics {#sec4.11}
----------

Wilcoxon rank sum test was performed to compare the percent *DAPK1* promoter methylation between CLL samples and normal controls and also to compare *DAPK1* expression in 50 unselected CLL samples with that of CD19+ normal B cells. To obtain proportions for the number of "A" or "G" clones in unaffected and affected family members and for the methylated and unmethylated CpGs within *DAPK1* promoter in Raji cells before and after decitabine treatment, the values were compared using the Z test (<http://faculty.vassar.edu/lowry/VassarStats.html>).
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![*DAPK1* Promoter Methylation in CLL Samples\
(A) Schematic representation of the *DAPK1* gene showing the location of the CpG island (black bar) and the four bisulfite reaction amplicons (A1--A4). The arrow indicates the predicted transcription start site. The lower panel shows a graphical display of quantitative DNA methylation data for the *DAPK1* promoter region. Each square represents a single CpG or a group of two or three CpGs analyzed, and each row represents a sample. Methylation frequencies extend from light yellow (0%) to dark blue (100%). Gray indicates unavailable data. Samples included seven CD19+ selected control B cells, four control normal PBMCs, seven CD19+ selected CLL cells, and PBMCs from 62 sporadic CLL samples, Raji and Jurkat cells. Asterisks indicate CLL samples that showed less than 11% methylation.\
(B) Plot of average percentage methylation in regions A1--A4, in controls (seven CD19+ selected B cells and four PBL samples; total = 11), CD19+ selected CLL cells (n = 7), unselected CLL cells (n = 62), and Raji and Jurkat cell lines.](gr1){#fig1}

![Epigenetic Silencing of *DAPK1* in CLL\
(A) pGL3 luciferase constructs ligated with different *DAPK1* 5′ upstream inserts (nos. 1--4) were transfected into Jurkat cells, and reporter activity was studied 48 hr after transfection. pGL3 vector without insert was used as a negative control. Error bars indicate standard deviation (SD).\
(B) Quantitative *DAPK1* expression in normal B cells and seven CD19+ selected CLL samples. The expression in CLL samples is shown relative to the expression in B cells (defined as 1.0). Error bars indicate SD.\
(C) Box plot of *DAPK1* expression in 50 CLL samples as measured by semiquantitative RT-PCR and compared to its expression in six normal B cell samples. The distribution is significantly different (p \< 0.01).\
(D) Luciferase assays in 293T cells with either methylated or unmethylated DAPK1 construct no. 2. Error bars indicate SD.\
(E) *DAPK1* expression in Raji cells treated with 0.5 μM decitabine. RT-PCR was performed for *DAPK1* and *GAPDH* on untreated and treated cell lines. Jurkat cells were used as a positive control.\
(F) Bisulfite sequences in BS1 region (c.1-1509--c.1-1262) for untreated, 6 and 12 days decitabine-treated (0.5 μM) Raji cells. Each row represents a clone. The open circles indicate unmethylated CpG, and closed circles indicate methylated CpG dinucleotides. The overall methylation frequency is given in percentage. Error bars indicate SD.](gr2){#fig2}

![DAPK1 Regulates Apoptosis in Lymphoid Cells\
(A) DAPK1 expression in Jurkat cells stably transfected with either vector alone, *DAPK1* siRNA-A, or *DAPK1* siRNA-C as measured by western blot. Tubulin expression served as a control.\
(B) Percent live cells were measured in Jurkat cells stably transfected with vector alone or *DAPK1* siRNA-C, treated with activating-Fas antibody (100 ng/ml). After 16 hr, cells were harvested and suspended in binding buffer with annexin V-FITC and propidium iodide, followed by flow cytometry to assess cell death. Error bars indicate SD.\
(C) p53 expression in cells treated with either no, 50 ng/ml, or 100 ng/ml Fas-activating antibody.](gr3){#fig3}

![*DAPK1* Expression in CLL Family 4532\
(A) Pedigree of CLL family no. 4532. Open circle and square represent unaffected female and male, respectively, while closed circle and square represent affected female and male.\
(B) Sequencing of SNP c.114A \> G from genomic DNA and cDNA of two unaffected (IV-3 and IV-4) and two affected (III-3 and III-4) individuals.\
(C) RT-PCR on RNA isolated from monochromosomal hybrid clones with either WT or the CLL chromosome 9 from fibroblast cells of individual III-4 is shown. *RPL4* expression was used as an internal control. Error bars indicate SD.\
(D) DAPK1 protein expression from WT and CLL alleles in monochromosomal hybrids. Jurkat and WaC3CD5 cells were used as positive controls, and NIH3T3 cells were used as the negative control to show specificity to human *DAPK1*.\
(E and F) The RT-PCR product amplifying SNP c.1510A \> G in unaffected (IV-3; E) and affected (III-4; F) fibroblast cell lines was cloned, and individual clones were genotyped. Shown is the percentage of A and G clones in IV-3 and III-4, and n is the number of clones studied. The difference in allelic expression of *DAPK1* in III-4 and IV-3 was statistically significant (p \< 0.01).](gr4){#fig4}

![An A to G Change at c.1-6531 bp Regulates *DAPK1* Expression in CLL Family\
(A) A 357 bp PCR product with SNP c.1-6531A \> G was ligated upstream to *DAPK1* promoter (c.1-2215--c.1-1151) luciferase construct with either A (DAP-A) or G (DAP-G) as SNP.\
(B) The *DAPK1* promoter alone (no. 1), DAP-A, or DAP-G constructs were transfected into Jurkat cells, and the luciferase activity was measured. Error bars indicate SD.\
(C) Nuclear extracts from Jurkat cells were analyzed by EMSA assay using WT or CLL oligo. Five specific bands (I--V) are marked.\
(D) Ten- or fifty-fold molar excess concentrations of cold oligos were used for competition assays. An unlabeled Oct-1 oligo was used as a negative control.\
(E) EMSA assays were performed using WT, WT mutant, CLL, and CLL mutant oligos. In mutant oligos, the adjacent bases to the c.1-6531 SNP were mutated.\
(F) For the supershift assay, antibodies against HOXB7, USF2, and MSX2 were added to the Jurkat nuclear extract, and gel shift was studied using the CLL oligo.](gr5){#fig5}

![Downregulation of *DAPK1* Expression by HOXB7\
(A and B) Fibroblast cell lines from affected (III-4) and unaffected (IV-4) family members were transfected with 60 nM of HOXB7 siRNA or scrambled siRNA, and *HOXB7* expression was studied at different time points by semiquantitative SYBR green RT-PCR. *HOXB7* expression in untreated cells was set as 1.0. Error bars indicate SD. (C and D) *DAPK1* expression was studied in the fibroblast cell lines transfected with HOXB7 siRNA or scrambled siRNA for different time points by quantitative SYBR green RT-PCR. *DAPK1* expression in untreated cells was set as 1.0. Error bars indicate SD.\
(E and F) Allele-specific expression of *DAPK1* in an affected (E) and unaffected (F) family member was studied in fibroblasts from III-4 and IV-4, before and after transfection of HOXB7 siRNA. RT-PCR products including SNP c.1510A\>G were cloned and genotyped. Shown is the percentage of the number of clones from the two alleles, and (n) indicates number of clones studied.](gr6){#fig6}

![*DAPK1* Expression and Promoter Methylation in CLL Cells of Family No. 4532\
(A) RT-PCR for *DAPK1* with *GAPDH* as an internal control on RNA extracted from blood cells of no. 4532 family members III-1, III-2, III-3, III-4 and IV-5 and from selected CD19+ normal B-cells from 3 healthy volunteers. Error bars indicate SD.\
(B) DNA methylation analysis in CLL cells from CD19+ selected control B-cells, total PBMCs from one unaffected family member (IV-1) and two affected individuals (III-1 and III-4). Bisulfite treated DNA was amplified for the BS1 and BS2 regions. Each row represents a clone. The open circles indicate unmethylated and closed circles indicate methylated CpGs.](gr7){#fig7}
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